Prodapt launches BoltSpeed, a BSS solution for fibre service providers
Prodapt, the largest and fastest-growing player in the Connectedness industry, today announced the launch of BoltSpeed, a business support system solution that brings together industry-leading SaaS products like Salesforce Communications Cloud, Aria, and MuleSoft to offer a one-stop managed services platform for service providers.
In the fast-paced digital era, fibre businesses are being tied up by elaborate licensing arrangements and long implementation cycles for their software needs. The need to engage with multiple vendors, tackle difficult integrations, and sift through siloed data have made it a complicated journey for businesses aiming to provide a delightful, omnichannel customer experience.
With pre-configured tools and capabilities bundled together, BoltSpeed eliminates multi-vendor hassle, and provides simplified and converged solution delivery for all software needs, including licensing, implementation, and support.
“Fibre service providers are navigating an evolving terrain marked by heightened competition and strong need for comprehensive solutioning. BoltSpeed combines the best of SaaS platforms for CRM, billing, and integrations for a simple and robust solution to support scale and growth, reduce costs, and accelerate into a connected future,” Smita Katariya, Global Head – BSS Practice, Prodapt.
BoltSpeed comes with TMF-compliant integration standards, enabling operators to scale up from the beginning. Operators can now switch from Capex-heavy solutions to a unique Pay-as-you-Go Opex model. By managing their entire BSS operations in one place, operators can reduce time to market for new product releases and achieve a higher return on investment.
“As global fibre network rollouts accelerate, fibre service providers need a dedicated SaaS BSS solution to streamline order-to-cash processes,” said Brendan O'Brien, Chief Innovation Officer at Aria Systems. “We are proud to be part of Prodapt’s BoltSpeed vision and to provide the Aria Billing Cloud as part of a comprehensive managed service with best-of-breed components.”
BoltSpeed provides rich insights on the entire customer journey, helping businesses shorten their integration time and offer connected customer experiences.
“Service providers are under more pressure than ever to find ways to create exceptional customer experiences while reducing onboarding and operational costs,” said David Fan, VP & GM of Communications Products at Salesforce. “Solutions like Prodapt’s new BoltSpeed help service providers get the most from Salesforce Communications Cloud and MuleSoft to provide connected and personalized experiences for their customers.”
About Prodapt
Prodapt is the largest and fastest-growing specialized player in the Connectedness industry. With its singular focus on the domain, Prodapt has built deep expertise in the most transformative technologies that connect our world.
Prodapt is a trusted partner for enterprises across all layers of the Connectedness vertical. We design, configure, and operate solutions across their digital landscape, network infrastructure, and business operations - and craft experiences that delight their customers.
Today, our clients connect 1.1 billion people and 5.4 billion devices, and are among the largest telecom, media, and internet firms in the world. Prodapt works with Meta, Google, Amazon, AT&T, Verizon, Vodafone, Liberty Global, Liberty Latin America, Claro, Lumen, Windstream, Rogers, Telus, KPN, Virgin Media, British Telecom, Deutsche Telekom, Cisco, Adtran, Samsung, and many more.
A “Great Place To Work® Certified™” company, Prodapt employs over 6,000 technology and domain experts in 30+ countries across North America, Latin America, Europe, Africa, and Asia. Prodapt is part of the 128-year-old business conglomerate, The Jhaver Group, which employs over 30,000 people across 80+ locations globally.
Visit www.prodapt.com for more information.
Follow us on LinkedIn, Instagram, Facebook, Twitter, and YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419006090/en/
Contact information
FOR FORTHER INFORMATION:
Ashok Nagaraj
94498 34080
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom